Organizations Filed Purposes:
TO RADICALLY ENABLE AND ADVANCE BIOMEDICAL DISCOVERY THROUGH THE DEVELOPMENT AND EXPLORATORY APPLICATION OF NEW TECHNOLOGIES AND APPROACHES FOR ILLUMINATING CELL AND TISSUE STATES AND FUNCTION. TO ACHIEVE THIS VISION, ALTIUS IS ESTABLISHING A WHOLLY NEW TYPE OF SCIENTIFIC AND TECHNOLOGICAL DISCOVERY ENVIRONMENT DESIGNED TO FOSTER LEAPS IN INNOVATION. ALTIUS WILL LEVERAGE ITS CUTTING-EDGE TECHNOLOGIES TO SPAN THE CHASM BETWEEN BASIC BIOLOGICAL DISCOVERIES RELATED TO THE FUNCTION OF CELLS AND TISSUES AND THE TRANSLATION OF THESE INSIGHTS INTO THE CLINICAL ARENA AND THE DEVELOPMENT OF NOVEL MEDICINES.
ALTIUS DIRECTLY CONDUCTS AN ACTIVE AND MULTIFACETED PROGRAM OF BIOTECHNOLOGY RESEARCH. WE CONDUCT A CONSIDERABLE MAJORITY OF RESEARCH PROGRAMS DIRECTLY IN OUR OWN RESEARCH LABORATORY FACILITY, LOCATED IN SEATTLE. THE MEDICAL RESEARCH ORGANIZATION PROGRAM IS INTENDED TO GENERATE, DEVELOP AND TRANSLATE TO CLINICAL USE REGULATORY GENOMIC AND OTHER TECHNOLOGIES THAT HAVE TRANSFORMATIVE POTENTIAL IN BASIC BIOLOGY, BIOMEDICINE AND PHARMACEUTICAL DEVELOPMENT AND VALIDATION. INITIAL EFFORTS OF OUR RESEARCH PROGRAM FOCUS ON DEVELOPING A RICHER UNDERSTANDING OF HUMAN CELL MODELS, TARGETS AND MECHANISMS, FOR THE PURPOSE OF DEVELOPING NEW THERAPIES FOR DISEASE. TO THIS END, THE ORGANIZATION WILL FOCUS DEVELOPMENT ON DRIVING THE SCALING AND TRANSLATIONAL VALIDATION OF EXISTING CUTTING EDGE RESEARCH PLATFORMS, INCLUDING REGULATORY GENOMIC ANALYSES AND GENOME ENGINEERING TECHNOLOGIES. REGULATORY GENOMIC ANALYSIS YIELDS A HIGH-CONTENT, QUANTITATIVE ASSESSMENT OF INDIVIDUAL REGULATORY ELEMENTS, WHICH PROVIDES HIGHLY SENSITIVE MARKERS OF CELLULAR RESPONSE TO DISEASE AND TO CURRENT AND PAST DRUG EXPOSURES. SUCH ASSESSMENTS INFORM WHAT TISSUE AND TARGET TO STUDY, HOW TO MODULATE A DRUG TARGET, ANTICIPATE OFF-TARGET EFFECTS, AND PROTOTYPE DRUG TREATMENT EFFECTS.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| John Stamatoyannopoulos | PRESIDENT/SCIENTIFIC DIRECTOR | 40 | $715,500 |
| Michael Cockril | CHIEF TECHNOLOGY OFFICER | 40 | $285,124 |
| Allister Funnell | DEPUTY DIRECTOR | 40 | $227,500 |
| Jeff Vierstra | PRINCIPAL INVESTIGATOR | 40 | $194,860 |
| Wouter Meuleman | PRINCIPAL INVESTIGATOR | 40 | $185,228 |
| Tim Mercer | PRINCIPAL INVESTIGATOR | 40 | $170,726 |
| Lori Tonnes-Priddy | SECRETARY | 5 | $71,205 |
| Peter Handrinos | BOARD MEMBER | 2 | $15,000 |
| Hal Dietz | BOARD MEMBER | 1 | $15,000 |
| Tony Wood | BOARD MEMBER | 0.5 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202023219349316342_public.xml